The European Union’s Joint Clinical Assessment (JCA) has been underway since January 2025. It aims to harmonize health technology assessments (HTAs) across member states.
A major focus is the growing recognition of the value of real-world evidence (RWE) in complementing RCT data, especially in areas where RCTs may be limited or infeasible or unethical.
Join the Prescient RWE Roundtable in April to learn more about how the JCA and other HTA advancements will impact future evidence generation needs for new product launches.
Speakers:
